Document is current

Article History

Received: 25 May 2020

Accepted: 5 October 2020

First Online: 30 October 2020

Ethics approval and consent to participate

: Ethical approval for this study was obtained through ethics committees at each site.

: Consent for publication was obtained from all participants prior to the study.

: JKB has been a consultant to, advisory board member of, and a speaker for Janssen Cilag BV, Eli Lilly, Shire, Lundbeck, Roche, and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents or royalties. CFB is director and shareholder in SBGNeuro Ltd. TB served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire, and Infectopharm. He received conference support or speaker’s fee by Lilly, Medice, and Shire. He received royalties from Hogrefe, Kohlhammer, CIP Medien, and Oxford University Press. TC has received consultancy from Roche and received book royalties from Guildford Press and Sage. DGM has been a consultant to, and advisory board member, for Roche and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. The present work is unrelated to the above grants and relationships. The other authors report no biomedical financial interests or potential conflicts of interest.